431 related articles for article (PubMed ID: 38107059)
1. Targeted therapies in bladder cancer: signaling pathways, applications, and challenges.
Peng M; Chu X; Peng Y; Li D; Zhang Z; Wang W; Zhou X; Xiao D; Yang X
MedComm (2020); 2023 Dec; 4(6):e455. PubMed ID: 38107059
[TBL] [Abstract][Full Text] [Related]
2. Targeted Molecular Therapeutics for Bladder Cancer-A New Option beyond the Mixed Fortunes of Immune Checkpoint Inhibitors?
Bednova O; Leyton JV
Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33019653
[TBL] [Abstract][Full Text] [Related]
3. Novel Combination Therapies for the Treatment of Bladder Cancer.
Peng M; Xiao D; Bu Y; Long J; Yang X; Lv S; Yang X
Front Oncol; 2020; 10():539527. PubMed ID: 33585182
[TBL] [Abstract][Full Text] [Related]
4. Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(24):1-48. PubMed ID: 23074402
[TBL] [Abstract][Full Text] [Related]
5. Advances in Antibody-Drug Conjugates in the Treatment of HER2-Positive Breast Cancer.
Yu Y; Wang J; Liao D; Zhang D; Li X; Jia Y; Kong F
Breast Cancer (Dove Med Press); 2022; 14():417-432. PubMed ID: 36532256
[TBL] [Abstract][Full Text] [Related]
6. Immune-Checkpoint Inhibitors in Advanced Bladder Cancer: Seize the Day.
Maiorano BA; De Giorgi U; Ciardiello D; Schinzari G; Cisternino A; Tortora G; Maiello E
Biomedicines; 2022 Feb; 10(2):. PubMed ID: 35203620
[TBL] [Abstract][Full Text] [Related]
7. Systemic treatments for metastatic cutaneous melanoma.
Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
[TBL] [Abstract][Full Text] [Related]
8. Oncogenic signaling pathways associated with immune evasion and resistance to immune checkpoint inhibitors in cancer.
Kobayashi Y; Lim SO; Yamaguchi H
Semin Cancer Biol; 2020 Oct; 65():51-64. PubMed ID: 31874279
[TBL] [Abstract][Full Text] [Related]
9. Understanding resistance to immune checkpoint inhibitors in advanced breast cancer.
Tarantino P; Barroso-Sousa R; Garrido-Castro AC; McAllister SS; Guerriero JL; Mittendorf E; Curigliano G; Tolaney SM
Expert Rev Anticancer Ther; 2022 Feb; 22(2):141-153. PubMed ID: 34919490
[TBL] [Abstract][Full Text] [Related]
10. Development of EGFR TKIs and Options to Manage Resistance of Third-Generation EGFR TKI Osimertinib: Conventional Ways and Immune Checkpoint Inhibitors.
Wu L; Ke L; Zhang Z; Yu J; Meng X
Front Oncol; 2020; 10():602762. PubMed ID: 33392095
[TBL] [Abstract][Full Text] [Related]
11. Antibody-drug conjugates: the evolving field of targeted chemotherapy for breast cancer treatment.
Nader-Marta G; Molinelli C; Debien V; Martins-Branco D; Aftimos P; de Azambuja E; Awada A
Ther Adv Med Oncol; 2023; 15():17588359231183679. PubMed ID: 37435563
[TBL] [Abstract][Full Text] [Related]
12. Recent Advances in Medical Therapy for Urological Cancers.
Yuasa T; Urasaki T; Oki R
Front Oncol; 2022; 12():746922. PubMed ID: 35444946
[TBL] [Abstract][Full Text] [Related]
13. The future of bladder cancer therapy: Optimizing the inhibition of the fibroblast growth factor receptor.
Morales-Barrera R; Suárez C; González M; Valverde C; Serra E; Mateo J; Raventos C; Maldonado X; Morote J; Carles J
Cancer Treat Rev; 2020 Jun; 86():102000. PubMed ID: 32203842
[TBL] [Abstract][Full Text] [Related]
14. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
Xing R; Gao J; Cui Q; Wang Q
Front Immunol; 2021; 12():783236. PubMed ID: 34899747
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of second-line ICIs combined with TKIs among patients with metastatic renal cell carcinoma: a real-world study.
Zhang H; Chen J; Zhang X; Zhu X; Wang Z; Sun G; Liang J; Chen Y; Shen Y; Liu J; Li X; Wei Q; Liu Z; Zeng H; Shen P
Immunotherapy; 2022 Apr; 14(5):309-320. PubMed ID: 35187953
[No Abstract] [Full Text] [Related]
16. Newly Approved and Emerging Agents in HER2-Positive Metastatic Breast Cancer.
Graff SL; Yan F; Abdou Y
Clin Breast Cancer; 2023 Oct; 23(7):e380-e393. PubMed ID: 37407378
[TBL] [Abstract][Full Text] [Related]
17. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
Xia L; Liu Y; Wang Y
Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
[TBL] [Abstract][Full Text] [Related]
18. Antibody-Drug Conjugates in Breast Cancer: Current Status and Future Directions.
Mark C; Lee JS; Cui X; Yuan Y
Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762027
[TBL] [Abstract][Full Text] [Related]
19. A deep learning-based system for survival benefit prediction of tyrosine kinase inhibitors and immune checkpoint inhibitors in stage IV non-small cell lung cancer patients: A multicenter, prognostic study.
Deng K; Wang L; Liu Y; Li X; Hou Q; Cao M; Ng NN; Wang H; Chen H; Yeom KW; Zhao M; Wu N; Gao P; Shi J; Liu Z; Li W; Tian J; Song J
EClinicalMedicine; 2022 Sep; 51():101541. PubMed ID: 35813093
[TBL] [Abstract][Full Text] [Related]
20. Clinical updates on tyrosine kinase inhibitors in HER2-positive breast cancer.
Singh DD; Lee HJ; Yadav DK
Front Pharmacol; 2022; 13():1089066. PubMed ID: 36578543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
